Kazia Therapeutics (KZIA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$8.4M

Net income growth (year over year)

−29.47%

Net margin

—

Return on equity

−108.35%

EPS (trailing twelve months)

−$7.52

Book value per share

$3.09

P/E (trailing twelve months)

—

Price to book

3.64

Debt to assets

34.66%

Payout ratio

—

Dividend yield

—

Company profile

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

• How do I buy stock in Kazia Therapeutics (KZIA)?

  KZIA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.